Pharmaceutical Technology

APRIL 13, 2023

For some therapy areas, such as dermatology, recent improvements in remote video capture quality allows more accurate virtual assessments, and analysis shows [6] that nearly 24% of dermatology DCTs now incorporate this virtual component. However, there is still some use of remote patient monitoring technologies.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Dermatology 130

XTalks

SEPTEMBER 22, 2022

GPP occurs in individuals with specific gene variations as it is a genetic disease , and variations in the genes IL36RN and AP1S3 are known to cause it. The role of the IL-36 receptor was confirmed in loss-of-function mutation studies in the IL-36 receptor antagonist gene. Waldman Department of Dermatology.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Dermatology 52

Scienmag

OCTOBER 25, 2020

A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online. The BRAF gene is involved in telling healthy cells when to grow and form new cells, […].

Trials 41

Trials Gene Drugs Clinical Trials 41

XTalks

MAY 31, 2022

Tapinarof treatment in a mouse model of psoriasis resulted in the downregulation of inflammatory cytokine expression in skin tissue, which involved IL17A , IL17F , IL19 , IL22 , IL23A and IL1B gene expression. At Dermavant, we are committed to advancing novel, patient-focused innovation in immuno-dermatology. Clinical Trials of Vtama.

FDA Approval 98

FDA Approval Clinical Trials Clinical Trials Trials 98

Scienmag

NOVEMBER 18, 2020

“Framing race […].

Gene 52

Gene Research Dermatology Scientist 52

The Pharma Data

MARCH 28, 2022

Boehringer Ingelheim announced today new data from the pivotal Effisayil™ 1 trial presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston. trial investigator and Chair, Department of Dermatology at The University of Alabama School of Medicine. had clear/almost clear skin.

Dermatology 52

Dermatology Trials Contract Manufacturing Medicine 52

pharmaphorum

JUNE 29, 2022

The group founded by entrepreneur Vivek Ramaswamy – which specialises in taking on surplus projects from other companies and taking the forward – is dropping six candidates, including three from its dermatology unit Dermavant.

Trials 52

Trials Dermatology Gene Therapy Drugs 52

The Pharma Data

DECEMBER 10, 2020

He became Head of Development for Rare Diseases and Gene Therapy in Sanofi-Genzyme’s office in Cambridge, Massachusetts. Dr Pirozzi subsequently was inspired to pursue a career in rare diseases after his daughter Valentina was diagnosed with a rare chromosomal syndrome, called Smith-Magenis Syndrome. positions he assumed in 2020.

Research 52

Research Doctor Doctors Medicine 52

The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

DECEMBER 17, 2020

Martin Carter Professor in Clinical Investigation and Head of the Laboratory of Investigative Dermatology at The Rockefeller University and Weinblatt is the co-director of Clinical Rheumatology at the Brigham and Women’s Hospital. Prior to SpringWorks, Smith was the executive vice president of Gene Therapy at Bamboo Therapeutics.

Development 52

Development Gene Therapy Engineer Life Science 52

The Pharma Data

JANUARY 13, 2021

(IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases. More information is available on the Company website at www.IPharmInc.com.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

Scienmag

OCTOBER 19, 2020

Garrido, CNIO The sophisticated human immune system has evolved to become an effective protection system against a great number of diseases, cancer being one of them. The immune system recognises and destroys cancer cells using a monitoring process called immunological surveillance.

Dermatology 52

Dermatology Allergies Gene Genetics 52

Scienmag

FEBRUARY 12, 2021

A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in people in late stages of one of the most aggressive forms of skin cancer, a new study finds. Led by NYU Grossman School of Medicine and Perlmutter Cancer Center researchers, […].

Gene 62

Gene DNA Medicine Research 62

The Pharma Data

MARCH 18, 2022

Lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) are two distinct inhibitory immune checkpoints that are often co-expressed on tumor-infiltrating lymphocytes, thus contributing to tumor-mediated T-cell exhaustion.2 1 Please see Important Safety Information below.

Antibody 52

Antibody HR Trials Dermatology 52

The Pharma Data

MARCH 16, 2021

These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. 26 Although the exact cause of PsA is unknown, genes, the immune system and environmental factors are all believed to play a role in disease onset.

Medicine 52

Medicine Doctors Doctor Development 52

The Pharma Data

AUGUST 3, 2021

Aimovig retains strong payer coverage and remains the segment leader within the preventive calcitonin gene-related peptide (CGRP) class. We expect that recovery in the dermatology segment will continue to progress over the coming quarters. and continued geographic expansion, including the launch in China.

Sales 52

Sales Production Antibody Development 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. Immune-Mediated Skin and Dermatologic Adverse Reactions. Administer corticosteroids for Grade 3 or 4 rash.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. Immune-Mediated Skin and Dermatologic Adverse Reactions. Administer corticosteroids for Grade 3 or 4 rash.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 15, 2020

Pfizer’s Rare Disease late-stage pipeline currently includes three gene therapy programs that, if successful, are expected to gain regulatory approval by the end of 2023, with an additional pipeline of 10 preclinical initiatives that are at various stages of maturity. Inflammation and Immunology.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

XTalks

DECEMBER 20, 2023

The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy. Check out this article to learn about the biotech companies that went public this year.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

XTalks

AUGUST 2, 2023

Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A. 2022 was the first year on market for cell-based gene therapies Abecma (Idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel) , which generated $388 million and $182 million, respectively. Both are anti-CD20 agents.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JANUARY 24, 2021

CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate. The drug was well tolerated and demonstrated clinically meaningful improvement in the Dermatology Life Quality Index (DLQI) and Patient-Oriented Eczema Measure IPOEM).

Trials 52

Trials Allergies In-Vitro Antibody 52